Related Experiment Video For assay
Updated: Apr 18, 2026

Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
Regulatory considerations for companion diagnostic devices
Eunice Y Lee1, Hsin-Chieh Jennifer Shen
1Division of Molecular Genetics & Pathology, Office of In Vitro Diagnostics & Radiological Health, Center for Devices & Radiological Health, US FDA, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Abstract:
The emergence of companion diagnostic devices has been spurred by drug discovery and development efforts towards targeted therapies, particularly in oncology. Companion diagnostics and their corresponding therapeutics are often codeveloped, or developed in parallel, to ensure the safe and effective use of the products. The regulatory framework for companion diagnostics has gradually evolved as a result of the essential role of diagnostic tests to identify the intended population for a corresponding treatment. Here, we describe the current regulatory model for companion diagnostics in the US and outline key strategies for a successful codevelopment program from the device perspective. We also discuss how technological advances and changes in clinical management may challenge the regulatory model in the future.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Therapeutic Drug Monitoring: Overview and Classification
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Regulation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Therapeutic Drug Monitoring: Affecting Factors

